pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

178 catalysts · 43 phase 2 completion · 26 phase 1 completion · 22 phase 1 2 completion · 21 phase 2 initiation · 18 phase 1 initiation · 13 phase 1 2 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 11 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: copd×TA: oncology×TA: dermatology×clear all
type
  • phase 2 completion43
  • phase 1 completion26
  • phase 1 2 completion22
  • phase 2 initiation21
  • phase 1 initiation18
  • phase 1 2 initiation13
phase 0 trial completion7
  • phase 3 completion5
  • phase 3 initiation4
  • constraining patent expiry europe3
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 30, 2026phase 1 completion85d agoKyowa Kirin Co Ltd — brentuximab vedotin (Phase I Trial Completion)brentuximab vedotin

    Therapy area: Oncology. Indication: Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome

    full page →brentuximab vedotin →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoShanghai Institute of Biological Products Co Ltd — SIBPA-13 (Phase I Trial Completion)SIBPA-13

    Therapy area: Oncology. Indication: Breast Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Non-Small Cell Lung Cancer, Solid Tumor

    full page →SIBPA-13 →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoSun Yat-sen University Hospital Seven — stiripentol (Phase I Trial Completion)stiripentol

    Therapy area: Oncology. Indication: Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer

    full page →stiripentol →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoNational Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)emavusertib hydrochloride

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

    full page →emavusertib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoUniversity of Texas MD Anderson Cancer Center — bevacizumab (Phase I Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Advanced Malignancy, Metastatic Cancer, Solid Tumor

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoSiteman Cancer Center — soficabtagene geleucel (Phase I Trial Completion)soficabtagene geleucel

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sezary Syndrome, T-Cell Leukemia, T-Cell Lymphomas, Transformed Mycosis Fungoides

    full page →soficabtagene geleucel →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoRevolution Medicines Inc — daraxonrasib (Phase I Trial Completion)daraxonrasib

    Therapy area: Oncology. Indication: Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor

    full page →daraxonrasib →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoOno Pharmaceutical Co Ltd — ONO-4578 (Phase I Trial Completion)ONO-4578

    Therapy area: Oncology. Indication: Breast Cancer, Hormone Sensitive Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →ONO-4578 →source: globaldata
    ›Apr 30, 2026phase 1 completion85d agoDaiichi Sankyo Co Ltd — raludotatug deruxtecan (Phase I Trial Completion)raludotatug deruxtecan

    Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Ovarian Cancer, Renal Cell Carcinoma

    full page →raludotatug deruxtecan →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoQilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)QLS-5212

    Therapy area: Oncology. Indication: Solid Tumor

    full page →QLS-5212 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoVanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)nivolumab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Oral Cavity (Mouth) Cancer, Squamous Cell Carcinoma

    full page →nivolumab →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

    Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

    full page →VC-005 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

    Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

    full page →MK-6050 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoGan & Lee Pharmaceuticals Co Ltd — GLR-2037 (Phase I Trial Initiation)GLR-2037

    Therapy area: Oncology. Indication: Prostate Cancer

    full page →GLR-2037 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoAvance Clinical Pty Ltd — ZE-740282 (Phase I Trial Initiation)ZE-740282

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myeloproliferative Disorders, Polycythemia Vera

    full page →ZE-740282 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoByterna Therapeutics Ltd — BR-101 (Phase I Trial Initiation)BR-101

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →BR-101 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoBristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)navlimetostat

    Therapy area: Oncology. Indication: Biliary Tumor, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

    full page →navlimetostat →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoShanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)HLX-3901

    Therapy area: Oncology. Indication: Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →HLX-3901 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoCentre Hospitalier Universitaire de Nice — Leucogenase (Phase I Trial Initiation)Leucogenase

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

    full page →Leucogenase →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoKexing Biopharm Co Ltd — GB-18 (Phase I Trial Initiation)GB-18

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cachexia, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor, Unspecified Cancer

    full page →GB-18 →source: globaldata
    ›Apr 30, 2026phase 1 initiation85d agoBeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)BGC-0979

    Therapy area: Oncology. Indication: Solid Tumor

    full page →BGC-0979 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoAbbVie Inc — blinatumomab (Phase I/II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

    full page →blinatumomab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoBellicum Pharmaceuticals Inc — acetaminophen (Phase I/II Trial Completion)acetaminophen ER

    Therapy area: Oncology. Indication: Breast Cancer, Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoIRCCS Foundation National Cancer Institute — bevacizumab (Phase I/II Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Metastatic Colorectal Cancer

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoZhongshan Hospital — iNKT Cell Immunotherapy (Phase I/II Trial Completion)iNKT Cell Immunotherapy

    Therapy area: Oncology. Indication: Bladder Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

    full page →iNKT Cell Immunotherapy →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoAmsterdam UMC — tremelimumab (Phase I/II Trial Completion)tremelimumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →tremelimumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoInstitute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

    full page →cyclophosphamide →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoZhejiang Doer Biologics Corp — DR-30206 (Phase I/II Trial Completion)DR-30206

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Cancer, Gastrointestinal Tumor, Metastatic Colorectal Cancer

    full page →DR-30206 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

    Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

    full page →verteporfin →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoLepu Biopharma Co Ltd — pucotenlimab (Phase I/II Trial Completion)pucotenlimab

    Therapy area: Oncology. Indication: Pancreatic Cancer

    full page →pucotenlimab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoJiangsu Hengrui Pharmaceuticals Co Ltd — adebrelimab (Phase I/II Trial Completion)adebrelimab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →adebrelimab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoMultitude therapeutics Inc — AMT-253 (Phase I/II Trial Completion)AMT-253

    Therapy area: Non Malignant Disorders, Oncology. Indication: Acral Lentiginous Melanoma, Cervical Cancer, Endometrial Cancer, Gynecological Cancer, Leiomyosarcoma, Melanoma, Metastatic Melanoma, Solid Tumor, Uterine Leiomyoma (Uterine Fibroids)

    full page →AMT-253 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoBayer AG — avelumab (Phase I/II Trial Completion)avelumab

    Therapy area: Oncology. Indication: Bone Metastasis, Malignant Neoplasms, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer

    full page →avelumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoAbbVie Inc — venetoclax (Phase I/II Trial Completion)venetoclax

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Leukemia, Leukemia, T-Cell Leukemia

    full page →venetoclax →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoAstraZeneca Plc — Calquence (Phase I/II Trial Completion)CALQUENCE

    Therapy area: Oncology. Indication: CNS Lymphoma, Diffuse Large B-Cell Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma

    full page →CALQUENCE →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoHenan Cancer Hospital — methotrexate (Phase I/II Trial Completion)Maxtrex

    Therapy area: Oncology. Indication: Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer

    full page →Maxtrex →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoArvinas Inc — samuraciclib (Phase I/II Trial Completion)samuraciclib

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →samuraciclib →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoChiba Cancer Center — nivolumab (Phase I/II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma), Basaloid Squamous Cell Carcinoma, Esophageal Cancer, Squamous Cell Carcinoma

    full page →nivolumab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoNational Cheng-Kung University Hospital — cisplatin (Phase I/II Trial Completion)cisplatin

    Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

    full page →cisplatin →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

    Therapy area: Dermatology. Indication: Vitiligo

    full page →afamelanotide →source: globaldata
    ›Apr 30, 2026phase 1 2 completion85d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

    Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

    full page →M-701 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoNational Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)PEP-CMV

    Therapy area: Oncology. Indication: Ependymoma, Glioma, High-Grade Glioma, Medulloblastoma

    full page →PEP-CMV →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoSichuan Kelun Pharmaceutical Co Ltd — SKB-103 (Phase I/II Trial Initiation)SKB-103

    Therapy area: Oncology. Indication: Solid Tumor

    full page →SKB-103 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoRemeGen Co Ltd — RC-288 (Phase I/II Trial Initiation)RC-288

    Therapy area: Oncology. Indication: Melanoma, Non-Small Cell Lung Cancer, Prostate Cancer, Small-Cell Lung Cancer, Solid Tumor

    full page →RC-288 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoFennec Pharmaceuticals Inc — sodium thiosulfate (Phase I/II Trial Initiation)sodium thiosulfate

    Therapy area: Ear Nose Throat Disorders, Oncology. Indication: Esophageal Cancer, Head And Neck Cancer, Hearing Disorders, Lung Cancer, Malignant Pleural Mesothelioma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor)

    full page →sodium thiosulfate →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoDartsbio Pharmaceutical (Guangdong) Co Ltd — DS-010 (Phase I/II Trial Initiation)DS-010

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Cachexia, Cancer Anorexia-Cachexia Syndrome, Solid Tumor

    full page →DS-010 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoInstitute of Hematology & Blood Diseases Hospital — azacitidine (Phase I/II Trial Initiation)Onureg

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)

    full page →Onureg →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoBeijing Bethune Charitable Foundation — bevacizumab (Phase I/II Trial Initiation)bevacizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoBeijing Eastern Biotech Co Ltd — JY-016 (Phase I/II Trial Initiation)JY-016

    Therapy area: Oncology. Indication: Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Recurrent Head And Neck Squamous Cell Carcinoma, Solid Tumor

    full page →JY-016 →source: globaldata
    ›Apr 30, 2026phase 1 2 initiation85d agoCompass Therapeutics Inc — CTX-471 (Phase I/II Trial Initiation)CTX-471

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Glioma, Recurrent Glioblastoma Multiforme (GBM)

    full page →CTX-471 →source: globaldata
    ← prev
    page 3 of 4
    next →
    $ARVN8.26000.00%
    $ABBV253.30-1.09%
    $RVMD183.03-0.14%
    $ONC323.15+1.01%
    $ABBV253.30-1.09%
    $FENC10.32-0.67%
    $MRK130.13+2.08%
    $COMP11.26-1.40%
    $AZN169.73+0.23%